Singapore markets closed

Galapagos NV (GLPG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
47.26-1.03 (-2.13%)
As of 11:38AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close48.29
Open48.29
Bid47.12 x 800
Ask47.19 x 800
Day's range46.95 - 48.35
52-week range46.95 - 123.03
Volume151,559
Avg. volume224,098
Market cap3.161B
Beta (5Y monthly)0.37
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • CNW Group

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

    NEW YORK, March 3, 2021 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contact Robert S.

  • Business Wire

    Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF

    Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. The decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies. Detailed data of the ISABELA studies will be presented at future medical meetings.

  • Business Wire

    Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

    Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib). This announcement follows a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for filgotinib in the treatment of RA.